Monitoring antimalarial drug resistance within national malaria control programmes: The EANMAT experience

Tropical Medicine and International Health

Volumn 6, Issue 11, 2001, Pages 891-898

  Mutabingwa, T K ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

Case management; Drug resistance; EANMAT; Monitoring resistance

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; FANSIDAR;

DISEASE CONTROL; DISEASE TREATMENT; DRUG RESISTANCE; MALARIA;

AFRICA; ARTICLE; CHEMOTHERAPY; DRUG SENSITIVITY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MALARIA; MALARIA CONTROL; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATIENT CARE; TREATMENT FAILURE;

AFRICA;

EID: 0034782015     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00799.x     Document Type: Article

References (7)

1. EANMAT: Origins and 'start-up'
2. EANMAT - Internal and external evaluation: The past, present and future
3. The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites
4. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
5. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania
6. Using evidence to change antimalarial drug policy in Kenya
7. Resistance to pyrimethamine-sulfadoxine in Plasmodium falciparum in 12 villages in NorthEast Tanzania and a test of chlorproguanil-dapsone